Brookline Capital Markets Predicts Oncobiologics Q1 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Equities research analysts at Brookline Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for Oncobiologics in a research report issued to clients and investors on Tuesday, August 18th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for Oncobiologics’ current full-year earnings is ($0.49) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q2 2027 earnings at ($0.03) EPS and Q3 2027 earnings at ($0.03) EPS.

Oncobiologics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.97 million.

OTLK has been the topic of a number of other reports. Wall Street Zen cut Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Oncobiologics in a research report on Friday, August 14th. Weiss Ratings upgraded Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. HC Wainwright boosted their price target on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, Ascendiant Capital Markets upped their price target on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.65.

Oncobiologics Price Performance

OTLK stock opened at $0.69 on Thursday. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39. The firm has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $0.71. The firm has a market cap of $102.54 million, a price-to-earnings ratio of -0.90 and a beta of 0.82.

Insider Activity at Oncobiologics

In other Oncobiologics news, Director Faisal Ghiath Sukhtian bought 95,398 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average cost of $1.05 per share, with a total value of $100,167.90. Following the completion of the purchase, the director directly owned 220,972 shares in the company, valued at approximately $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Ghiath M. Sukhtian acquired 8,539,709 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were bought at an average price of $0.59 per share, with a total value of $5,038,428.31. Following the transaction, the director directly owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. The trade was a 63.01% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 11,189,359 shares of company stock worth $7,662,666 in the last ninety days. Corporate insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Oncobiologics

A number of large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after acquiring an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.